{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:24:49Z","timestamp":1787984689946,"version":"build-2784847793"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bando Ricerca Salute Regione Toscana 2018"},{"name":"Parent Project Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Duchenne muscular dystrophy (DMD) is a devastatingly severe genetic muscle disease characterized\u00a0by childhood-onset muscle weakness, leading to loss of motor function and premature death due to respiratory and\u00a0cardiac insufficiency.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>In the following three and half decades, DMD kept its paradigmatic role in the\u00a0field of muscle diseases, with first systematic description of disease progression with ad hoc outcome measures\u00a0and the first attempts at correcting the disease-causing gene defect by several molecular targets. Clinical trials are\u00a0critical for developing and evaluating new treatments for DMD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the last 20 years, research efforts\u00a0converged in characterization of the disease mechanism and development of therapeutic strategies. Same effort\u00a0needs to be dedicated to the development of outcome measures able to capture clinical benefit in clinical trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-022-06085-w","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T04:04:16Z","timestamp":1653365056000},"page":"625-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy"],"prefix":"10.1007","volume":"43","author":[{"given":"Giulia","family":"Ricci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Torri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Schirinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6142-2384","authenticated-orcid":false,"given":"Gabriele","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"6085_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N et al (2017) The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis 12:79. https:\/\/doi.org\/10.1186\/s13023-017-0631-3","journal-title":"Orphanet J Rare Dis"},{"key":"6085_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","volume":"359","author":"AEH Emery","year":"2002","unstructured":"Emery AEH (2002) The muscular dystrophies. Lancet 359:687\u2013695. https:\/\/doi.org\/10.1016\/S0140-6736(02)07815-7","journal-title":"Lancet"},{"key":"6085_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/mus.10435","volume":"28","author":"KL Tyler","year":"2003","unstructured":"Tyler KL (2003) Origins and early descriptions of Duchenne muscular dystrophy? Muscle Nerve 28:402\u2013422. https:\/\/doi.org\/10.1002\/mus.10435","journal-title":"Muscle Nerve"},{"key":"6085_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928","journal-title":"Cell"},{"key":"6085_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","volume":"50","author":"M Koenig","year":"1987","unstructured":"Koenig M, Hoffman EP, Bertelson CJ et al (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509\u2013517. https:\/\/doi.org\/10.1016\/0092-8674(87)90504-6","journal-title":"Cell"},{"key":"6085_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S et al (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90\u201395","journal-title":"Genomics"},{"key":"6085_CR7","doi-asserted-by":"publisher","unstructured":"Matthews E, Brassington R, Kuntzer T et al (2016) Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev CD003725. https:\/\/doi.org\/10.1002\/14651858.CD003725.pub4","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"6085_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2013) The cooperative international neuromuscular research group Duchenne natural history study\u2013a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 48:32\u201354. https:\/\/doi.org\/10.1002\/mus.23807","journal-title":"Muscle Nerve"},{"key":"6085_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","volume":"77","author":"E Mazzone","year":"2011","unstructured":"Mazzone E, Vasco G, Sormani MP et al (2011) Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77:250\u2013256. https:\/\/doi.org\/10.1212\/WNL.0b013e318225ab2e","journal-title":"Neurology"},{"key":"6085_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","volume":"15","author":"IEC Verhaart","year":"2019","unstructured":"Verhaart IEC, Aartsma-Rus A (2019) Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol 15:373\u2013386. https:\/\/doi.org\/10.1038\/s41582-019-0203-3","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"6085_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C (2010) DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9(1):77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6","journal-title":"Lancet Neurol"},{"issue":"4","key":"6085_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM (2018) DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347\u2013361. https:\/\/doi.org\/10.1016\/S1474-4422(18)30025-5","journal-title":"Lancet Neurol"},{"issue":"5","key":"6085_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, Cripe L, Herron AR, Kennedy A, Kinnett K, Naprawa J, Noritz G, Poysky J, Street N, Trout CJ, Weber DR (2018) Ward LM (2018) DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17(5):445\u2013455. https:\/\/doi.org\/10.1016\/S1474-4422(18)30026-7","journal-title":"Lancet Neurol"},{"key":"6085_CR14","doi-asserted-by":"publisher","unstructured":"Matthews E, Brassington R, Kuntzer T et al (2016) Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev (5):CD003725. https:\/\/doi.org\/10.1002\/14651858","DOI":"10.1002\/14651858"},{"key":"6085_CR15","unstructured":"American Academy of Neurology. Practice guideline update summary: corticosteroid treatment of duchenne muscular dystrophy. aan. com\/Guidelines\/home\/GuidelineDetail\/731. Accessed August 21, 2019"},{"issue":"10","key":"6085_CR16","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/emmm.201302621","volume":"5","author":"CR Heier","year":"2013","unstructured":"Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, Sali A, Miller BK, Phadke A, Scheffer L, Quinn J, Tatem K, Jordan S, Dadgar S, Rodriguez OC, Albanese C, Calhoun M, Gordish-Dressman H, Jaiswal JK, Connor EM, McCall JM, Hoffman EP, Reeves EK, Nagaraju K (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 5(10):1569\u20131585","journal-title":"EMBO Mol Med"},{"issue":"1","key":"6085_CR17","first-page":"16","volume":"30","author":"S Messina","year":"2011","unstructured":"Messina S, Vita GL, Aguennouz M, Sframeli M, Romeo S, Rodolico C, Vita G (2011) Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol 30(1):16\u201323","journal-title":"Acta Myol"},{"issue":"6","key":"6085_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/01.wnl.0000173836.09176.c4","volume":"65","author":"YW Chen","year":"2005","unstructured":"Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP (2005) Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65(6):826\u2013834","journal-title":"Neurology"},{"issue":"23","key":"6085_CR19","doi-asserted-by":"publisher","first-page":"15000","DOI":"10.1073\/pnas.192571199","volume":"99","author":"JN Haslett","year":"2002","unstructured":"Haslett JN, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, Kohane IS, Beggs AH, Kunkel LM (2002) Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A 99(23):15000\u201315005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6085_CR20","doi-asserted-by":"publisher","first-page":"e201800186","DOI":"10.26508\/lsa.201800186","volume":"2","author":"CR Heier","year":"2019","unstructured":"Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF (2019) Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance 2(1):e201800186. https:\/\/doi.org\/10.26508\/lsa.201800186","journal-title":"Life Sci Alliance"},{"issue":"12","key":"6085_CR21","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP et al (2015) Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology 85(12):1048\u20131055. https:\/\/doi.org\/10.1212\/WNL.0000000000001950","journal-title":"Neurology"},{"key":"6085_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","volume":"58","author":"M Guglieri","year":"2017","unstructured":"Guglieri M, Bushby K, McDermott MP et al (2017) Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemp Clin Trials 58:34\u201339. https:\/\/doi.org\/10.1016\/j.cct.2017.04.008","journal-title":"Contemp Clin Trials"},{"issue":"10119","key":"6085_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, Clemens PR, Hoffman EP, Cnaan A, Gordish-Dressman H, Investigators C (2018) Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391(10119):451\u2013461","journal-title":"Lancet"},{"issue":"8","key":"6085_CR24","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","volume":"21","author":"EKM Reeves","year":"2013","unstructured":"Reeves EKM, Hoffman EP, Nagaraju K, Damsker JM, McCall JM (2013) VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem 21(8):2241\u20132249","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"6085_CR25","doi-asserted-by":"publisher","first-page":"e201800186","DOI":"10.26508\/lsa.201800186","volume":"2","author":"CR Heier","year":"2019","unstructured":"Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF (2019) Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance 2(1):e201800186. https:\/\/doi.org\/10.26508\/lsa.201800186","journal-title":"Life Sci Alliance"},{"issue":"5","key":"6085_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jcph.842","volume":"57","author":"JM Donovan","year":"2017","unstructured":"Donovan JM, Zimmer M, Offman E, Grant T, Jirousek M (2017) A Novel NF-\u03baB Inhibitor, Edasalonexent (CAT-1004), in Development as a disease-modifying treatment for patients with Duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects. J Clin Pharmacol 57(5):627\u2013639. https:\/\/doi.org\/10.1002\/jcph.842","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"6085_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nmd.2021.02.001","volume":"31","author":"RS Finkel","year":"2021","unstructured":"Finkel RS, Finanger E, Vandenborne K, Sweeney HL, Tennekoon G, Shieh PB, Willcocks R, Walter G, Rooney WD, Forbes SC, Triplett WT, Yum SW, Mancini M, MacDougall J, Fretzen A, Bista P, Nichols A, Donovan JM (2021) Disease-modifying effects of edasalonexent, an NF-\u03baB inhibitor, in young boys with Duchenne muscular dystrophy: results of the MoveDMD phase 2 and open label extension trial. Neuromuscul Disord 31(5):385\u2013396. https:\/\/doi.org\/10.1016\/j.nmd.2021.02.001","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"6085_CR28","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/ana.24370","volume":"77","author":"L Bello","year":"2015","unstructured":"Bello L, Kesari A, Gordish-Dressman H et al (2015) Genetic modifiers of ambulation in the cooperative international neuromuscular research group Duchenne natural history study. Ann Neurol 77(4):684\u2013696. https:\/\/doi.org\/10.1002\/ana.24370","journal-title":"Ann Neurol"},{"key":"6085_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1212\/WNL.45.4.677","volume":"45","author":"E Pegoraro","year":"1995","unstructured":"Pegoraro E, Schimke RN, Garcia C et al (1995) Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology 45:677\u2013690. https:\/\/doi.org\/10.1212\/WNL.45.4.677","journal-title":"Neurology"},{"key":"6085_CR30","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1093\/brain\/awr291","volume":"134","author":"K Anthony","year":"2011","unstructured":"Anthony K, Cirak S, Torelli S et al (2011) Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials. Brain 134:3544\u20133556. https:\/\/doi.org\/10.1093\/brain\/awr291","journal-title":"Brain"},{"key":"6085_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","volume":"28","author":"N Goemans","year":"2018","unstructured":"Goemans N, Mercuri E, Belousova E et al (2018) A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscul Disord 28:4\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2017.10.004","journal-title":"Neuromuscul Disord"},{"key":"6085_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.nmd.2015.10.007","volume":"25","author":"V Ricotti","year":"2015","unstructured":"Ricotti V, Muntoni F, Voit T (2015) Challenges of clinical trial design for DMD. Neuromuscul Disord 25:932\u2013935. https:\/\/doi.org\/10.1016\/j.nmd.2015.10.007","journal-title":"Neuromuscul Disord"},{"key":"6085_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982","journal-title":"Ann Neurol"},{"key":"6085_CR34","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0657","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus A, Krieg AM (2016) FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid Ther. https:\/\/doi.org\/10.1089\/nat.2016.0657","journal-title":"Nucleic Acid Ther"},{"key":"6085_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"Y-A Heo","year":"2020","unstructured":"Heo Y-A (2020) Golodirsen: First Approval. Drugs 80:329\u2013333. https:\/\/doi.org\/10.1007\/s40265-020-01267-2","journal-title":"Drugs"},{"key":"6085_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/nat.2018.0756","volume":"29","author":"A Aartsma-Rus","year":"2019","unstructured":"Aartsma-Rus A, Goemans N (2019) A sequel to the eteplirsen saga: eteplirsen is approved in the United States but was not approved in Europe. Nucleic Acid Ther 29:13\u201315. https:\/\/doi.org\/10.1089\/nat.2018.0756","journal-title":"Nucleic Acid Ther"},{"key":"6085_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24842","author":"EF Unger","year":"2016","unstructured":"Unger EF, Califf RM (2016) Regarding eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.24842","journal-title":"Ann Neurol"},{"key":"6085_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24843","author":"JR Mendell","year":"2016","unstructured":"Mendell JR (2016) Eteplirsen improves function and partially restores dystrophin. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.24843","journal-title":"Ann Neurol"},{"key":"6085_CR39","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","volume":"17","author":"H Yin","year":"2008","unstructured":"Yin H, Moulton HM, Seow Y et al (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17:3909\u20133918. https:\/\/doi.org\/10.1093\/hmg\/ddn293","journal-title":"Hum Mol Genet"},{"key":"6085_CR40","doi-asserted-by":"publisher","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","volume":"8","author":"RS Finkel","year":"2013","unstructured":"Finkel RS, Flanigan KM, Wong B et al (2013) Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One 8:e81302. https:\/\/doi.org\/10.1371\/journal.pone.0081302","journal-title":"PLoS One"},{"key":"6085_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B et al (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50:477\u2013487. https:\/\/doi.org\/10.1002\/mus.24332","journal-title":"Muscle Nerve"},{"key":"6085_CR42","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1096\/fj.13-240044","volume":"28","author":"M Li","year":"2014","unstructured":"Li M, Andersson-Lendahl M, Sejersen T, Arner A (2014) Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment. FASEB J 28:1593\u20131599. https:\/\/doi.org\/10.1096\/fj.13-240044","journal-title":"FASEB J"},{"key":"6085_CR43","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE et al (2017) Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1489\u20131498. https:\/\/doi.org\/10.1016\/S0140-6736(17)31611-2","journal-title":"Lancet"},{"key":"6085_CR44","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","volume":"74","author":"NJ Ryan","year":"2014","unstructured":"Ryan NJ (2014) Ataluren: first global approval. Drugs 74:1709\u20131714. https:\/\/doi.org\/10.1007\/s40265-014-0287-4","journal-title":"Drugs"},{"key":"6085_CR45","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/cer-2019-0086","volume":"8","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Desguerre I, Guglieri M et al (2019) Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry. J Comp Eff Res 8:1187\u20131200. https:\/\/doi.org\/10.2217\/cer-2019-0086","journal-title":"J Comp Eff Res"},{"key":"6085_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/cer-2019-0171","volume":"9","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Muntoni F, Osorio AN et al (2020) Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res 9:341\u2013360. https:\/\/doi.org\/10.2217\/cer-2019-0171","journal-title":"J Comp Eff Res"},{"issue":"1","key":"6085_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2119\/molmed.2013.00011","volume":"19","author":"S Consalvi","year":"2013","unstructured":"Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del Bene F, Rocchetti M, Leoni F, Monzani V, Mascagni P, Puri PL, Saccone V (2013) Preclinical studies in the mdx mouse model of Duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med 19(1):79\u201387. https:\/\/doi.org\/10.2119\/molmed.2013.00011","journal-title":"Mol Med"},{"issue":"10","key":"6085_CR48","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D\u2019Oria V, D\u2019Amico A, Catteruccia M, Pane M, Sivo S, Magri F, Brajkovic S, Messina S, Vita GL, Gatti B, Moggio M, Puri PL, Rocchetti M, De Nicolao G, Vita G, Comi GP, Bertini E, Mercuri E (2016) Histological effects of Givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord 26(10):643\u2013649. https:\/\/doi.org\/10.1016\/j.nmd.2016.07.002","journal-title":"Neuromuscul Disord"},{"key":"6085_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-319-67144-4_5","volume":"1031","author":"R Thompson","year":"2017","unstructured":"Thompson R, Robertson A, Lochm\u00fcller H (2017) Natural history, trial readiness and gene discovery: advances in patient registries for neuromuscular disease. Adv Exp Med Biol 1031:97\u2013124","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"6085_CR50","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.4155\/cli.11.113","volume":"1","author":"K Bushby","year":"2011","unstructured":"Bushby K, Connor E (2011) Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond) 1(9):1217\u20131235","journal-title":"Clin Investig (Lond)"},{"issue":"3","key":"6085_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mus.23905","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2013) The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48(3):357\u2013368. https:\/\/doi.org\/10.1002\/mus.23905","journal-title":"Muscle Nerve"},{"key":"6085_CR52","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/adc.2007.123653","volume":"93","author":"AE Lammers","year":"2008","unstructured":"Lammers AE et al (2008) The 6-minute walk test: normal values for children of 4\u201311 years of age. Arch Dis Child 93:464\u2013468","journal-title":"Arch Dis Child"},{"issue":"11","key":"6085_CR53","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","volume":"20","author":"E Mazzone","year":"2010","unstructured":"Mazzone E, Martinelli D, Berardinelli A, Messina S, D\u2019Amico A, Vasco G, Main M, Doglio L, Politano L, Cavallaro F, Frosini S, Bello L, Carlesi A, Bonetti AM, Zucchini E, De Sanctis R, Scutifero M, Bianco F, Rossi F, Motta MC, Sacco A, Donati MA, Mongini T, Pini A, Battini R, Pegoraro E, Pane M, Pasquini E, Bruno C, Vita G, de Waure C, Bertini E, Mercuri E (2010) North star ambulatory assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 20(11):712\u2013716. https:\/\/doi.org\/10.1016\/j.nmd.2010.06.014","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"6085_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12955-021-01813-w","volume":"19","author":"H Staunton","year":"2021","unstructured":"Staunton H, Trennery C, Arbuckle R, Guridi M, Zhuravleva E, Furlong P, Fischer R, Hall R (2021) Development of a clinical global impression of change (CGI-C) and a caregiver global impression of change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy. Health Qual Life Outcomes 19(1):184. https:\/\/doi.org\/10.1186\/s12955-021-01813-w","journal-title":"Health Qual Life Outcomes"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06085-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T04:23:43Z","timestamp":1671769423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06085-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":54,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6085"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06085-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"6 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}